New strategies in radioimmunotherapy for lymphoma

被引：10

作者：

Neeta Pandit-Taskar

Paul A. Hamlin

Susan Reyes

Steven M. Larson

Chaitanya R. Divgi

机构：

[1] Department of Radiology, Mem. Sloan-Kettering Cancer Center, New York, NY 10021

来源：

Current Oncology Reports | 2003年 / 5卷 / 5期

关键词：

Mantle Cell Lymphoma; Overall Response Rate; Indolent Lymphoma; Tositumomab; Ibritumomab Tiuxetan;

D O I：

10.1007/s11912-003-0020-z

中图分类号：

学科分类号：

摘要：

Treatment options for patients with indolent non-Hodgkin's lymphoma historically involved radiation or chemotherapy. Although initial response rates are excellent, treatment is increasingly less effective with each successive relapse. The advent of immunotherapy heralds a new era for the treatment of these patients. Radioimmunotherapy adds the benefits of cytotoxic radiation to immunotherapy and represents a significant addition to the treatment armamentarium. Various antigens for lymphoma have been targeted, of which anti-CD20 antibodies are the furthest in development. Ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA), a 90yttrium-labeled agent, and 131iodine-labeled tositumomab (Bexxar; Corixa, Seatle, WA are approved by the US Food and Drug Administration. Both agents have shown utility in therapy for relapsed and refractory low-grade and transformed lymphomas. This review highlights features of radioimmunotherapy that are relevant to non-Hodgkin's lymphoma, focusing on the two anti-CD20 antibodies. Copyright© 2003 by Current Science Inc.

引用

页码：364 / 371

页数：7

共 69 条

[1]

Jemal A., Murray T., Samuels A., Et al., Cancer statistics, 2003, CA Cancer J. Clin., 53, pp. 5-26, (2003)

[2]

Harris N.L., Jaffe E.S., Diebold J., Et al., World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997, J. Clin. Oncol., 17, pp. 3835-3849, (1999)

[3]

Armitage J.O., Weisenburger D.D., New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project, J. Clin. Oncol., 16, pp. 2780-2795, (1998)

[4]

Fisher R.I., Gaynor E.R., Dahlberg S., Et al., Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma, N. Engl. J. Med., 328, pp. 1002-1006, (1993)

[5]

Horning S.J., Natural history of and therapy for the indolent non-Hodgkin's lymphomas, Semin Oncol, 20, 5 SUPPL., pp. 75-88, (1993)

[6]

McLaughlin P., Grillo-Lopez A.J., Link B.K., Et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, J. Clin. Oncol., 16, pp. 2825-2833, (1998)

[7]

Piro L.D., White C.A., Grillo-Lopez A.J., Et al., Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma, Ann. Oncol., 10, pp. 655-661, (1999)

[8]

Colombat P., Salles G., Brousse N., Et al., Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation, Blood, 97, pp. 101-106, (2001)

[9]

Hainsworth J.D., Burris III H.A., Morrissey L.H., Et al., Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma, Blood, 95, pp. 3052-3056, (2000)

[10]

Czuczman M.S., CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma, Semin. Oncol., 26, SUPPL. 14, pp. 88-96, (1999)

← 1 2 3 4 5 6 7 →